ASCO 2016: James Kochenderfer/NIH on Inducing Remissions in B-Cell Lymphoma: ascopost.com/videos/2016-as... Good summary of recent NIH CAR-T trial for DLBCL and fNHL. Long durations for those who achieve a CR.
ASCO 2016: NIH CAR-T Trial : ASCO 2016: James... - CLL Support
ASCO 2016: NIH CAR-T Trial
Written by
wmay13241
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Axi-Cel (anti-CD19 CAR T-cell therapy FMC63-28Z) Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma
Patients with relapsed chronic lymphocytic leukemia (CLL) and B-cell lymphoma who received the...
Dr Sharman provides an update on an NIH CAR-T trial for relapsed/refractory DBLC
Many of us will remember the excitement a couple of years back when Dr Carl June of the University...
Secondary Cancers after CAR-T Cell Therapy
From New England Journal of Medicine dated 24th Jan 2024 (article is for subscribers only)
This...
CLL Society Dr. Koffman's ASCO 2020 "Top 12" Picks #s 12, 11, 10
Dr. Koffman’s ASCO 2020 “Top 12” Picks
The 2020 Annual Meeting of the American Society of Clinical...
ASH 2019: A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma
"Conclusion:
This study demonstrates that it is safe to administrate a single dose of Sativex to...
Related Posts
ASCO 2016: Dr. Susan O’Brien where she discusses frontline data on Acalabrutinib in CLL
CAR-T coming to OSU Medical Center- How Ibrutinib works over time
- Latest update on CAR-T (CTL019) personalized cellular therapy for CLL
- CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
